ResMed Inc. (RMD) News
Follow ResMed Inc. (RMD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 38 public stories across 23 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
ResMed Reports Fiscal Q3 2026 Revenue of $1.41B, EPS of $2.92
ResMed reported revenue of $1.41 billion, up 5.9% year over year. Net income rose 20% to $418.41 million and diluted EPS increased 23.2% to $2.92.
EQUITY | Oct 30, 2026, 10:11 AM UTC
M
ResMed Publishes Q1 FY2027 Earnings Call Transcript
ResMed published a transcript of its Q1 fiscal 2027 earnings call.
EQUITY | Oct 30, 2026, 06:15 AM UTC
M
ResMed Reports Quarterly Results for Quarter Ended September 30
The LSEG-generated earnings summary provides no results figures in the supplied text.
EQUITY | Oct 29, 2026, 10:48 PM UTC
M
Resmed Q1 Profit Rises to $418.413 Million
Resmed reported first-quarter profit of $418.413 million, or $2.92 per share, compared with $348.536 million, or $2.37 per share, a year earlier.
EQUITY | Oct 29, 2026, 08:44 PM UTC
M
ResMed Sees FY27 Core Constant Currency Revenue Growth of 5%–7%
EARNINGS | Oct 29, 2026, 08:36 PM UTC
M
Resmed Q1 Revenue Beats Estimates on Sleep Device and Mask Demand
EQUITY | Oct 29, 2026, 08:27 PM UTC
M
ResMed Reports 1Q Revenue of $1.41B
EARNINGS | Oct 29, 2026, 08:12 PM UTC
M
ResMed Reports First-Quarter Adjusted EPS of $2.91
EARNINGS | Oct 29, 2026, 08:12 PM UTC
L
ResMed Reports 1Q Net Income of $418.4M
EARNINGS | Oct 29, 2026, 08:06 PM UTC
L
ResMed reports first-quarter EPS of $2.92
EARNINGS | Oct 29, 2026, 08:06 PM UTC
M
ResMed Q3 Earnings Preview: What to Watch
ResMed is scheduled to report results Thursday after market hours. The preview cites last quarter’s revenue of $1.46 billion, up 8.6% year over year, and says revenue met analyst expectations.
EQUITY | Oct 28, 2026, 03:09 AM UTC
M
ResMed Q1'27 Results Preview
ResMed is scheduled to report Q1'27 results on October 29 before the market opens. Revenue and EPS estimates are provided ahead of the report.
EQUITY | Oct 22, 2026, 11:01 AM UTC
L
Resmed launches AirTouch F40 CPAP mask in the U.S.
Resmed launched the AirTouch F40 full-face fabric CPAP mask in the U.S.
EQUITY | Oct 19, 2026, 12:00 PM UTC
H
ResMed Q4 2026 Earnings Call Transcript
ResMed (NYSE: RMD ) reported fourth-quarter financial results on Thursday. The transcript from the company's fourth-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcript
LIVE | Oct 12, 2026, 11:43 AM UTC
H
Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7%
U.S. stocks slipped by midday Wednesday as a sharp selloff in industrials weighed on the Dow Jones and small caps, while healthcare provided a rare pocket of strength. The S&P 500 fell 0.4% to 7,788, while the Dow Jones
LIVE | Oct 07, 2026, 04:53 PM UTC
M
Resmed to report Q1 fiscal 2027 earnings Oct. 29, 2026
EQUITY | Oct 01, 2026, 08:05 PM UTC
H
Weekly Recap: FY guidance reaffirmed and Astral retirement, $42M charge
ResMed Inc. (NYSE:RMD) reaffirmed fiscal targets while reshaping its device lineup—retiring the Astral platform with a $42M charge and halting new Astral sales in FY27, pivoting NIV to AirCurve S/ST/ST—A on Air11, and cl
EARNINGS | Sep 28, 2026, 11:05 AM UTC
M
ResMed upgraded to Outperform as price target raised
RBC Capital upgraded ResMed to Outperform from Sector Perform and lifted its price target to $262 from $244.
EQUITY | Sep 15, 2026, 08:07 PM UTC
H
RMD: Volume-driven growth, digital engagement, and portfolio shifts drive robust outlook
Guidance was provided for 5%-7% revenue growth, with strong volume-driven performance and ongoing margin expansion through supply chain productivity. GLP-1s and consumer tech are fueling patient funnel growth, while acqu
EARNINGS | Sep 15, 2026, 03:42 PM UTC
H
RMD: Volume-driven growth, tech innovation, and GLP-1s fuel strong performance and expanding margins
Guidance was provided for 5%-7% revenue growth, with strong volume-driven performance and expanding margins. Strategic acquisitions, tech partnerships, and AI-driven patient engagement are enhancing adherence and support
EARNINGS | Sep 15, 2026, 03:05 PM UTC
L
ResMed Price Target Raised to $262.00/Share From $244.00 by RBC Capital
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 02:26 PM UTC
L
ResMed upgraded at RBC Capital Markets on Q4 positives
RBC Capital Markets on Tuesday upgraded ResMed NYSE:RMD to Outperform from Sector Perform and raised its price target to $262 from $244, citing positives in the respiratory device maker’s Q4 results for fiscal 2026.Share
EARNINGS | Sep 15, 2026, 02:01 PM UTC
H
DELAYED UPDATE — ResMed reports FY2026 revenue up 8% and launches $450M ASR
ResMed reported fiscal 2026 revenue of $5.7B, up 8% YoY, citing margin expansion and strong buybacks. It started a $450M accelerated repurchase using cash and MatrixCare sale proceeds and guided to higher fiscal 2027 rev
EARNINGS | Sep 07, 2026, 11:24 AM UTC
M
ResMed to buy back $450 million in stock under ASR
ResMed will buy back $450 million of stock under an accelerated share repurchase agreement with Citibank, using a 20 million-share repurchase authorization from 2014.
EQUITY | Sep 01, 2026, 09:16 PM UTC
L
ResMed enters accelerated share repurchase agreement for $450 million stock
ResMed (NYSE:RMD) entered an accelerated share repurchase agreement to repurchase $450 million of common stock, per an SEC filing.
REGULATION | Sep 01, 2026, 08:39 PM UTC
L
ResMed to participate in Morgan Stanley Global Healthcare Conference
ResMed said it will participate in the 24th Annual Morgan Stanley Global Healthcare Conference.
EQUITY | Aug 27, 2026, 08:07 PM UTC
L
RMD announces participation in 24th Morgan Stanley healthcare conference
RMD said it will participate in the 24th Annual Morgan Stanley Global Healthcare Conference.
EQUITY | Aug 27, 2026, 08:05 PM UTC
L
How high can BHP go? Plus: uranium, lithium and copper commodity charts and ASX sector reviews
How high can BHP go? Plus: uranium, lithium and copper commodity charts and ASX sector reviews
COMMODITIES | Aug 26, 2026, 11:37 PM UTC
L
RMD - 23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs - Click
RMD - 23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
EQUITY | Aug 25, 2026, 01:00 PM UTC
L
Near 200dma support LIN KKR OGE MCK STE APG MLI WRB FHB GMED SRPT UTHR GNRC GNTX CMI RITM WTM RMD WFRD
Near 200dma support LIN KKR OGE MCK STE APG MLI WRB FHB GMED SRPT UTHR GNRC GNTX CMI RITM WTM RMD WFRD
EQUITY | Aug 20, 2026, 07:27 PM UTC
L
Redburn starts RMD at Neutral with $230 price target
Redburn initiates coverage of RMD at Neutral with a $230 price target, according to the alert.
EQUITY | Aug 19, 2026, 11:55 AM UTC
L
Resmed appoints Carol Burt as lead director, plans Ron Taylor retirement
Resmed appoints Carol Burt as lead director and says director Ron Taylor plans to retire.
REGULATION | Aug 17, 2026, 08:10 PM UTC
H
Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq 100 futures gaining over 100 points on Friday. Shares of Trade Desk Inc (NASDAQ: TTD ) fell sharply in pre-market trading after the company reported worse-than-
EARNINGS | Aug 07, 2026, 12:02 PM UTC
L
RMD Downgrade from Outperform to Sector Perform W/$234.00 PT at RBC Capital
RMD Downgrade from Outperform to Sector Perform W/$234.00 PT at RBC Capital
EQUITY | Jul 16, 2026, 11:54 AM UTC
L
RMD cleveland Medical Devices: in four of five proceedings, ptab determined that Co had not established that challenged claims were unpatent
RMD cleveland Medical Devices: in four of five proceedings, ptab determined that Co had not established that challenged claims were unpatentable
EQUITY | Jul 13, 2026, 08:27 PM UTC
L
RMD cleveland Medical Devices: won favorable ptab outcomes in 5 of 6 ResMed ipr challenges
RMD cleveland Medical Devices: won favorable ptab outcomes in 5 of 6 ResMed ipr challenges
EQUITY | Jul 13, 2026, 08:26 PM UTC
L
Resmed Insider Sold Shares Worth $1,090,771, According to a Recent SEC Filing
() -- Michael J. Farrell, Director, Chairman and Chief Executive Officer, on July 07, 2026, sold 4,991 shares in Resmed (RMD) for $1,090,771. Following the Form 4 filing with the SEC, Farrell has control over a total of
REGULATION | Jul 09, 2026, 11:56 AM UTC
M
RMD: Keybanc Maintains Overweight
Keybanc maintains overweight rating on ResMed and lowers price target to $266
EQUITY | Jun 22, 2026, 01:15 PM UTC